The purpose of the study was to identify Candida infections in cancer patients and examine treatment response. and evaluating the effectiveness of specific antifungal drugs in treating the illness as well as the resistance of the isolated antifungal strains. The number of samples (serum) were 125, collected from cancer patients, whose ages ranged between (20 year - 60 years) with a date of infection with candidiasis during the period from (October to December 2023). All specimens were collected from Al-Najaf Governorate.
The results showed that 59% of cancer cases are associated with fungal infections (candidiasis), with 49 samples being Candida albicans, 4 samples being C.tropicalis, 5 samples being C.glabrata, and one sample being C.parapslosis, while the results of the sensitivity test showed 45 samples are sensitive to two types of antifungals (Nystatin and Fluconazole), and 14 samples are resistant to these antifungals.
Samples
Antifungal
2 samples
resistant to fluconazole
6 samples
resistant to nystatin
6 samples
resistant to fluconazole and nystatin